Nektar Therapeutics

Healthcare · Biotechnology · United States

Last price 39.18 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.34B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has col...